Suppliers and packagers for generic pharmaceutical drug: AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ajanta Pharma Ltd	AMLODIPINE AND OLMESARTAN MEDOXOMIL	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	207216	ANDA	Ajanta Pharma USA Inc.	27241-083-03	30 TABLET in 1 BOTTLE (27241-083-03)	2017-02-06
Ajanta Pharma Ltd	AMLODIPINE AND OLMESARTAN MEDOXOMIL	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	207216	ANDA	Ajanta Pharma USA Inc.	27241-083-09	90 TABLET in 1 BOTTLE (27241-083-09)	2017-02-06
Ajanta Pharma Ltd	AMLODIPINE AND OLMESARTAN MEDOXOMIL	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	207216	ANDA	Ajanta Pharma USA Inc.	27241-084-03	30 TABLET in 1 BOTTLE (27241-084-03)	2017-02-06

API Suppliers for AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

Last updated: February 19, 2026

This report identifies key Active Pharmaceutical Ingredient (API) suppliers for Amlodipine Besylate and Olmesartan Medoxomil, two widely prescribed cardiovascular medications. The analysis focuses on suppliers with demonstrated regulatory compliance, significant production capacity, and a track record of consistent supply. This information is critical for pharmaceutical manufacturers evaluating supply chain stability, potential cost savings, and risk mitigation strategies.

What are the key APIs in question?

The APIs are Amlodipine Besylate and Olmesartan Medoxomil. Amlodipine Besylate is a dihydropyridine calcium channel blocker used to treat high blood pressure and chest pain (angina). Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) used to treat high blood pressure. These two APIs are frequently combined in fixed-dose combination medications for enhanced therapeutic effect [1].

Who are the primary manufacturers and suppliers of Amlodipine Besylate API?

Manufacturing and supply of Amlodipine Besylate API are concentrated among several key global players. Companies with significant market presence and regulatory filings include:

• Torrent Pharmaceuticals Ltd.: An Indian multinational pharmaceutical company. Torrent has a strong presence in generics and intermediates.
• Dr. Reddy's Laboratories Ltd.: Another major Indian pharmaceutical company with a global footprint in API manufacturing.
• Sun Pharmaceutical Industries Ltd.: A leading Indian pharmaceutical company with extensive API production capabilities.
• Cipla Ltd.: An Indian multinational pharmaceutical company with a diversified API portfolio.
• Lupin Ltd.: An Indian multinational pharmaceutical company known for its generics and API development.
• Teva Pharmaceutical Industries Ltd.: A global leader in generics and biosimil manufacturing.
• Mylan N.V. (now part of Viatris): A significant player in the generics market with substantial API manufacturing.
• Aurobindo Pharma Ltd.: An Indian multinational pharmaceutical company with a broad API manufacturing base.

These companies often operate integrated manufacturing facilities, from basic chemical synthesis to the final API. Their regulatory submissions, including Drug Master Files (DMFs), are crucial for market access in regulated regions like the United States and Europe.

What are the primary manufacturers and suppliers of Olmesartan Medoxomil API?

The Olmesartan Medoxomil API market is also characterized by a few dominant suppliers, predominantly from India and China, alongside some established Western players. Key entities include:

• Daiichi Sankyo Company, Limited: The originator of Olmesartan Medoxomil, retaining significant manufacturing capabilities and intellectual property.
• Aurobindo Pharma Ltd.: A major supplier with robust manufacturing and a strong regulatory filing history for Olmesartan Medoxomil.
• Dr. Reddy's Laboratories Ltd.: Active in producing Olmesartan Medoxomil API for global markets.
• Sun Pharmaceutical Industries Ltd.: A significant contributor to the global supply of Olmesartan Medoxomil API.
• Torrent Pharmaceuticals Ltd.: Involved in the supply chain for this critical API.
• Hetero Drugs Ltd.: An Indian pharmaceutical company with substantial API manufacturing capacity.
• Zydus Lifesciences Ltd. (formerly Cadila Healthcare Ltd.): Another Indian pharmaceutical group with API production.
• Jiangsu Hengrui Medicine Co., Ltd.: A prominent Chinese pharmaceutical company with growing API export capabilities.

The production of Olmesartan Medoxomil involves complex multi-step synthesis, requiring specialized chemical expertise and stringent quality control.

What is the typical regulatory landscape for these APIs?

The regulatory landscape for Amlodipine Besylate and Olmesartan Medoxomil APIs is governed by major health authorities worldwide. Key aspects include:

• Drug Master Files (DMFs): Manufacturers must submit DMFs to regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These confidential documents contain detailed information about the manufacturing process, facilities, quality controls, and stability of the API. Pharmaceutical companies referencing these DMFs in their drug product applications rely on them for regulatory approval.
• Good Manufacturing Practices (GMP): All API manufacturing facilities must adhere to stringent GMP guidelines. Regulatory agencies conduct regular inspections to ensure compliance. Non-compliance can lead to warning letters, import alerts, and market exclusion.
• Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP): For APIs intended for the European market, obtaining a CEP from the European Directorate for the Quality of Medicines & HealthCare (EDQM) is a common pathway to demonstrate compliance with European Pharmacopoeia (Ph. Eur.) standards.
• Inspections and Audits: Pharmaceutical companies purchasing APIs conduct their own audits of API manufacturers to ensure quality, reliability, and adherence to regulatory standards. These audits are critical for supply chain due diligence.
• Intellectual Property (IP) and Patents: While the core patents for Amlodipine and Olmesartan have expired in many regions, leading to a generic market, specific manufacturing processes or polymorphs may still be protected. Companies must navigate the IP landscape to avoid infringement.

How do API quality and regulatory compliance impact supply chain reliability?

API quality and regulatory compliance are foundational to supply chain reliability for Amlodipine Besylate and Olmesartan Medoxomil.

• Quality Consistency: APIs must consistently meet predefined specifications (e.g., purity, impurity profiles, particle size distribution) to ensure the safety and efficacy of the final drug product. Deviations can lead to batch rejections, recalls, and regulatory actions.
• Regulatory Approvals: Manufacturers with approved DMFs and a history of successful regulatory inspections by agencies like the FDA and EMA are inherently more reliable. Their processes are validated, and their quality systems are robust.
• Supply Chain Disruption Mitigation: Suppliers with multiple manufacturing sites or robust business continuity plans are better positioned to mitigate disruptions caused by natural disasters, geopolitical events, or regulatory issues at a specific facility.
• Auditable Processes: Reliable suppliers maintain transparent and well-documented manufacturing and quality control processes that are auditable by their customers and regulators. This transparency builds trust and reduces supply risk.
• Technical Support: Reliable API suppliers offer strong technical support, assisting drug product manufacturers with formulation challenges, regulatory inquiries, and process optimization.

A supplier’s ability to consistently deliver high-quality API that meets all regulatory requirements is a direct predictor of supply chain stability. Companies with a strong track record in these areas minimize the risk of stock-outs, quality failures, and regulatory non-compliance, which are critical for uninterrupted patient access to essential medications.

What are the key considerations for sourcing these APIs?

Sourcing Amlodipine Besylate and Olmesartan Medoxomil APIs requires a multi-faceted approach, balancing cost, quality, and reliability. Key considerations include:

• Supplier Qualification: Conduct thorough due diligence on potential suppliers. This includes reviewing their regulatory history (DMF status, inspection reports), quality management systems (ISO certifications, GMP compliance), manufacturing capabilities, and financial stability.
• Regulatory Filings: Verify that suppliers have active and accepted DMFs or CEPs in the target markets. Understand the status and history of their regulatory filings, including any past warning letters or import alerts.
• Quality Agreements: Establish comprehensive quality agreements with chosen suppliers. These agreements define responsibilities for quality control, change management, deviation handling, and issue resolution.
• Supply Chain Visibility and Transparency: Seek suppliers who can provide transparency into their manufacturing processes, raw material sourcing, and production schedules. This enables better demand forecasting and risk management.
• Capacity and Scalability: Assess the supplier's production capacity to meet current and future demand. Discuss their ability to scale up production in response to market growth or unexpected demand surges.
• Cost and Pricing Stability: While cost is a significant factor, it should not be the sole determinant. Evaluate pricing structures for potential volatility and seek long-term supply agreements that offer some level of price stability. Compare pricing across multiple qualified suppliers.
• Geopolitical and Supply Chain Risk: Diversify supplier base where feasible to mitigate risks associated with single-country reliance or geopolitical instability. Consider suppliers from different geographic regions with robust regulatory frameworks.
• Technical Expertise and Support: Select suppliers who can provide robust technical support for product development, troubleshooting, and regulatory assistance. Their R&D capabilities can be valuable.
• Lead Times and Delivery Reliability: Understand supplier lead times for production and delivery. Track historical delivery performance to gauge reliability.
• Auditing: Implement a program for regular customer audits of supplier facilities. These audits confirm ongoing compliance with quality and regulatory standards.

A strategic sourcing approach prioritizes long-term partnerships built on trust, transparency, and a shared commitment to quality and regulatory compliance.

How has the market for these APIs evolved, and what are the current trends?

The market for Amlodipine Besylate and Olmesartan Medoxomil APIs has evolved significantly, driven by patent expirations and the rise of generic drug manufacturing. Current trends include:

• Dominance of Generic Manufacturers: With the expiry of key patents, the market is largely supplied by generic API manufacturers, primarily from India and China, offering competitive pricing.
• Consolidation in the API Sector: The API manufacturing sector has seen some consolidation, with larger players acquiring smaller ones to expand their product portfolios, geographical reach, and manufacturing capacity.
• Increased Regulatory Scrutiny: Global regulatory agencies are intensifying their scrutiny of API manufacturing facilities, particularly concerning data integrity, impurity control, and GMP compliance. This leads to greater differentiation between compliant and non-compliant suppliers.
• Focus on Impurity Profiling: There is a heightened focus on identifying, quantifying, and controlling impurities, especially genotoxic impurities, in APIs. Manufacturers must invest in advanced analytical technologies and robust process controls.
• Supply Chain Resilience: Recent global events have underscored the fragility of global supply chains. Pharmaceutical companies are increasingly seeking to diversify their API supplier base, build strategic inventory, and demand greater transparency and risk management from their suppliers.
• Advancements in Process Chemistry: Continuous efforts are made to optimize synthesis routes, improve yields, reduce environmental impact, and enhance cost-effectiveness through process chemistry innovations.
• Emergence of New Suppliers: While established players dominate, there is a gradual emergence of new suppliers from regions with developing pharmaceutical manufacturing capabilities, provided they meet stringent quality and regulatory standards.

These trends indicate a dynamic market where quality, regulatory adherence, and robust supply chain management are paramount for success.

What are the implications for pharmaceutical companies?

The dynamics of the Amlodipine Besylate and Olmesartan Medoxomil API markets have direct implications for pharmaceutical companies:

• Cost Optimization: The availability of multiple generic suppliers allows for competitive pricing, enabling significant cost savings for drug product manufacturers. However, careful supplier selection is necessary to avoid compromising quality for price.
• Supply Chain Risk Management: Companies must actively manage the risks associated with API sourcing. This includes diversifying suppliers, conducting thorough due diligence, establishing strong quality agreements, and monitoring geopolitical and regulatory developments that could impact supply.
• Regulatory Compliance Burden: Pharmaceutical companies are responsible for ensuring that the APIs they use are manufactured in compliance with all applicable regulations. This requires ongoing engagement with API suppliers and regular audits.
• Strategic Partnerships: Building strong, long-term relationships with reliable API suppliers can foster collaboration on process improvements, new product development, and ensuring consistent supply during market fluctuations.
• Quality Assurance Investment: Companies must invest in their internal quality assurance capabilities to effectively evaluate and monitor API suppliers. This includes having experienced personnel for audits, technical reviews, and quality oversight.
• Market Access and Timeliness: The ability to secure a reliable supply of high-quality APIs is crucial for bringing generic drugs to market efficiently and for maintaining consistent product availability to patients. Delays or quality issues with APIs can significantly impact market entry and revenue.
• Intellectual Property Navigation: While patents on the core molecules have expired, companies must remain vigilant about potential patent issues related to specific manufacturing processes or crystalline forms.

Effectively navigating these implications requires a proactive and strategic approach to API sourcing and supply chain management.

Key Takeaways

• The Amlodipine Besylate and Olmesartan Medoxomil API markets are dominated by established generic manufacturers, primarily from India and China.
• Regulatory compliance, demonstrated through approved DMFs and successful GMP inspections by authorities like the FDA and EMA, is critical for supplier qualification and supply chain reliability.
• Quality consistency, impurity control, and adherence to stringent pharmacopoeial standards are paramount for ensuring the safety and efficacy of final drug products.
• Pharmaceutical companies must implement robust supplier qualification programs, establish comprehensive quality agreements, and conduct regular audits to mitigate supply chain risks.
• Current market trends emphasize supply chain resilience, increased regulatory scrutiny, and advancements in process chemistry, requiring continuous adaptation from both API manufacturers and drug product formulators.
• Strategic sourcing decisions should balance cost considerations with the critical factors of quality, regulatory compliance, and long-term supply security.

FAQs

1. Which regulatory bodies' inspections are most critical for API suppliers of Amlodipine Besylate and Olmesartan Medoxomil? Inspections by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are most critical due to the significant market share of these regions for cardiovascular medications. Inspections by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and by Australia's Therapeutic Goods Administration (TGA) are also important for specific markets.

2. What is the typical lead time for securing a new API supplier for Amlodipine Besylate or Olmesartan Medoxomil? Securing a new API supplier typically involves a comprehensive qualification process that can take 6 to 12 months or longer. This includes initial audits, technical data review, sample testing, and potentially an on-site validation audit by the pharmaceutical company.

3. How do price fluctuations in raw materials impact the cost of Amlodipine Besylate and Olmesartan Medoxomil APIs? The synthesis of these APIs involves multiple chemical intermediates. Price volatility of key starting materials or reagents can directly influence the cost of the final API. Manufacturers with integrated backward integration or long-term raw material contracts are better positioned to mitigate these fluctuations.

4. What are the primary risks associated with sourcing APIs from a single supplier for these drugs? The primary risks include supply chain disruption due to the supplier's manufacturing issues (e.g., quality control failures, natural disasters, regulatory actions), increased dependency on their pricing strategies, and potential limitations in scaling up production if demand unexpectedly surges.

5. Are there specific impurity concerns for Amlodipine Besylate or Olmesartan Medoxomil that drug product manufacturers should be aware of when selecting an API supplier? For Amlodipine Besylate, related substances and degradation products are key concerns. For Olmesartan Medoxomil, specific impurities arising from the synthesis, such as those related to nitrozamines (though less common than with some other ARBs), and process-related impurities require careful monitoring and control by the API supplier and verification by the drug product manufacturer. Regulatory bodies have increased scrutiny on nitrosamine impurities across various drug classes.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Approval Process. Retrieved from https://www.fda.gov/drugs/development-approval-process (General reference for drug approval and API importance)